155. Dydyk AM, Sizemore DC, Trachsel LA, Dulebohn, SC, Porter, BR. (2022) Tennessee Controlled Substance Prescribing For Acute and Chronic Pain. In: StatPearls [Internet]. Retrieved September 22, 2022 from https://www.ncbi.nlm.nih.gov/books/ NBK567756/ 156. Centers for Disease Control and Prevention (CDC). (n.d.). Calculating total daily dosage of opioids for safer dosage. Retrieved September 22, 2022 from https://www.cdc.gov/drugoverdose/pdf/ calculating_total_daily_dose-a.pdf 157. Rosenquist, R. (2022). Abuse deterrent opioids. Retrieved September 22, 2022 from https://www. uptodate.com/contents/abuse-deterrent-opioids 158. Cicero, T. J., Ellis, M. S., & Surratt, H. J. (2012). Effect of abuse-deterrent formulation of OxyContin. New England Journal of Medicine, 367, 187–189. 159. Munzing, T. (2017). Physician guide to appropriate opioid prescribing for noncancer pain. The Permanente Journal, 21, 16-169. https://doi. org/10.7812/TPP/16-169 160. Murphy, D. L., Lebin, J. A., Severtson, S. G., Olsen, H. A., Dasgupta, N., & Dart, R. C. (2018). Comparative rates of mortality and serious adverse effects among commonly prescribed opioid analgesics. Drug Safety, 41(8), 787-795. https:// doi.org/10.1007/s40264-018-0660-4 161. Camilleri, M., Lembo, A., & Katzka, D. A. (2017). Opioids in gastroenterology: Treating adverse effects and creating therapeutic benefits. Clinical Gastroenterology and Hepatology, 15(9), 1338- 1349. https://doi.org/10.1016/j.cgh.2017.05.014 162. Lind, J. N., Interrante, J. D., Ailes, E. C., Gilboa, S. M., Khan, S., Frey, M. T., Dawson, A. L., Honein, M. A., Dowling, N. F., Razzaghi, H., Creanga, A. A., & Broussard, C. S. (2017). Maternal use of opioids during pregnancy and congenital malformations: A systematic review. Pediatrics, 139(6), e20164131. https://doi.org/10.1542/peds.2016-4131 163. Nebraska Department of Health & Human Services. (2017a). Nebraska pain management guidance document. Retrieved September 22, 2022 from https://dhhs.ne.gov/DOP%20document%20 library/Pain%20Management%20Pain%20 Guidance.pdf 164. Chou, R., Fanciullo, G. J., Fine, P. G., Adler, J. A., Ballantyne, J. C., Davies, P., Donovan, M. I., Fishbain, D. A., Foley, K. M., Fudin, J., Gilson, A. M., Kelter, A., Mauskop, A., O’Connor, P. G., Passik, S. D., Pasternak, G. W., Portenoy, R. K., Rich, B. A., Roberts, R. G., Todd, K. H., … American Pain Society-American Academy of Pain Medicine Opioids Guidelines Panel (2009). Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain. The journal of pain, 10(2), 113–130. https:// doi.org/10.1016/j.jpain.2008.10.008 165. Portenoy, RK; Mehta, Z; Ahmed, E. (2022). Prevention and management of side effects in patients receiving opioids for chronic pain. Retrieved September 22, 2022 from https:// www.uptodate.com/contents/prevention-and- management-of-side-effects-in-patients-receiving- opioids-for-chronic-pain 166. MedLaw, Dr. (2016). Avoid patient abandonment: 8 tips for termination. Physician’s Weekly. Retrieved September 22, 2022 from https:// www.physiciansweekly.com/avoiding-patient- abandonment-proper-termination 167. American Medical Association. (2017). Promote safe storage and disposal of opioids and all medications. Retrieved September 22, 2022 from https://www.aafp.org/dam/AAFP/documents/ patient_care/pain_management/safe-storage.pdf
168. Food and Drug Administration (FDA). (2021). Where and how to dispose of unused medicines. Retrieved September 22, 2022 from https://www. fda.gov/consumers/consumer-updates/where-and- how-dispose-unused-medicines 169. Lowey S. E. (2020). Management of Severe Pain in Terminally Ill Patients at Home: An Evidence-Based Strategy. Home healthcare now, 38(1), 8–15. https://doi.org/10.1097/ NHH.0000000000000826 170. Broglio K, Cole B. (2011). Pain Management and Terminal Illness. Practical Pain Management. Retrieved September 16, 2022 from https://www. practicalpainmanagement.com/resources/hospice/ pain-management-terminal-illness 171. American Society of Addiction Medicine. (2020). The ASAM Clinical Practice Guideline on Alcohol Withdrawal Management. Journal of addiction medicine, 14(3S Suppl 1), 1–72. https://doi. org/10.1097/ADM.0000000000000668 172. National Institute on Drug Abuse. (2018). The science of drug use and addiction: the basics. Retrieved July 29, 2022 from https://www. drugabuse.gov/publications/media-guide/science- drug-use-addiction-basics 173. American Psychiatric Association. (2013). Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5). Arlington, VA. Retrieved July 29, 2022 from https://dsm. psychiatryonline.org/doi/book/10.1176/appi. books.9780890425596 174. National Institute on Drug Abuse [NIDA]. (2020). Principles of Effective Treatment. Retrieved July 29, 2022 from https://nida.nih.gov/publications/ principles-drug-addiction-treatment-research- based-guide-third-edition/principles-effective- treatment 175. Volkow, N., Wise, R. & Baler, R. (2017). The dopamine motive system: implications for drug and food addiction. Nat Rev Neurosci 18, 741–752 https://doi.org/10.1038/nrn.2017.130 176. Uhl, G. R., Koob, G. F., & Cable, J. (2019). The neurobiology of addiction. Annals of the New York Academy of Sciences, 1451(1), 5–28. https://doi. org/10.1111/nyas.13989 177. Ouzir, M., & Errami, M. (2016). Etiological theories of addiction: A comprehensive update on neurobiological, genetic and behavioural vulnerability. Pharmacology, biochemistry, and behavior, 148, 59–68. https://doi.org/10.1016/j. pbb.2016.06.005 178. Substance Abuse and Mental Health Services Ad- ministration (SAMHSA). (2021). Key substance use and mental health indicators in the United States: Results from the 2020 National Survey on Drug Use and Health. Retrieved September 6, 2022 from https://www.samhsa.gov/data/sites/default/ files/reports/rpt35325/NSDUHFFRPDFWHTML- Files2020/2020NSDUHFFR1PDFW102121.pdf 179. Grant, B. F., Saha, T. D., Ruan, W. J., Goldstein, R. B., Chou, S. P., Jung, J., … Hasin, D. S. (2016). Epidemiology of DSM-5 drug use disorder: Results from the National Epidemiologic Survey on Alcohol and Related Conditions-III. JAMA Psychiatry, 73(1), 39-47. doi: 10.1001/jamapsychiatry.2015.2132 180. Centers for Disease Control and Prevention. (2021). Understanding the epidemic. https://www. cdc.gov/drugoverdose/epidemic/index.html 181. Webster, L. R. (2017). Risk factors for opioid- use disorder and overdose. Anesthesia and Analgesia, 125(5), 1741–1748. https://doi. org/10.1213/ANE.0000000000002496
182. Dowell, D., Haegerich, T. M., & Chou R. (2016). CDC guideline for prescribing opioids in pain—United States. JAMA, 315(15), 1624–1645. doi:10.1001/ jama.2016.1464 183. American Academy of Family Physicians [AAFP]. (2016). Chronic Pain Management and Opioid Misuse: A Public Health Concern (Position Paper). Retrieved July 29, 2022 from https://www.aafp. org/about/policies/all/chronic-pain-management- opiod-misuse.html. 184. Strain, E. (2021). Opioid use disorder: Epidemiology, pharmacology, clinical manifestations, course, screening, assessment, and diagnosis. Retrieved July 29, 2022 from https://www.uptodate. com/contents/opioid-use-disorder-epidemiology- pharmacology-clinical-manifestations-course- screening-assessment-and-diagnosis 185. Bisaga, A., Mannelli, P., Sullivan, M. A., Vosburg, S. K., Compton, P., Woody, G. E., & Kosten, T. R. (2018). Antagonists in the medical management of opioid use disorders: Historical and existing treatment strategies. The American Journal on Addictions, 27(3), 177-187. doi: 10.1111/ajad.12711 186. Srivastava, A. B., Mariani, J. J., & Levin, F. R. (2020). New directions in the treatment of opioid withdrawal. Lancet (London, England), 395(10241), 1938–1948. https://doi. org/10.1016/S0140-6736(20)30852-7 187. American Society of Addiction Medicine. (2020b). The ASAM National Practice Guideline for the Treatment of Opioid Use Disorder: 2020 Focused Update. Journal of addiction medicine, 14(2S Suppl 1), 1–91. https://doi.org/10.1097/ ADM.0000000000000633 188. Substance Abuse and Mental Health Services Administration (SAMHSA). (2021b). Pharmacist verification of buprenorphine providers. https:// www.samhsa.gov/medication-assisted-treatment/ pharmacist-verification 189. Ali, S., Tahir, B., Jabeen, S., & Malik, M. (2017). Methadone treatment of opiate addiction: A systematic review of comparative studies. Innovations in Clinical Neuroscience, 14(7-8), 8-19. https://www.ncbi.nlm.nih.gov/pmc/articles/ PMC5880371/ 190. Chou, R., Cruciani, R. A., Fiellin, D. A., Compton, P., Farrar, J. T., Haigney, M. C., … Zeltzer, L. (2014). Methadone safety: A clinical practice guideline from the American Pain Society and College on Problems of Drug Dependence, in collaboration with the Heart Rhythm Society. The Journal of Pain, 15(4), 321-37. doi: 10.1016/j.jpain.2014.01.494. 191. Substance Abuse and Mental Health Services Administration (SAMHSA). (2022). Medication Assisted Treatment (MAT). Retrieved August 29, 2022 from https://www.samhsa.gov/medication- assisted-treatment 192. Saxon, A; Strain, E; Peavy, M. (2021). Approach to treating opioid use disorder. Retrieved August 28, 2022 from https://www.uptodate.com/contents/ approach-to-treating-opioid-use-disorder 193. Mayet, S., Farrell, M., Ferri, M., Amato, L., & Davoli, M. (2005). Psychosocial treatment for opiate abuse and dependence. The Cochrane database of systematic reviews, (1), CD004330. https://doi. org/10.1002/14651858.CD004330.pub2 194. Bruneau, J., Ahamad, K., Goyer, M. È., Poulin, G., Selby, P., Fischer, B., Wild, T. C., Wood, E., & CIHR Canadian Research Initiative in Substance Misuse (2018). Management of opioid use disorders: a national clinical practice guideline. CMAJ : Canadian Medical Association journal = journal de l’Association medicale canadienne, 190(9), E247– E257. https://doi.org/10.1503/cmaj.170958
43
Powered by FlippingBook